Merck & Co., Inc. $MRK Stake Boosted by MassMutual Private Wealth & Trust FSB

Key Points

• MassMutual Private Wealth & Trust FSB increased its stake in Merck & Co., Inc. by 2.4% during Q2, owning 157,068 shares valued at $12.43 million.
• Merck's latest earnings report showed a $2.13 earnings per share, exceeding expectations, but revenue fell short at $15.81 billion versus the predicted $15.92 billion.
• The company declared a quarterly dividend of $0.81 per share, representing an annual yield of 4.0%, with the payout date set for October 7th.

MassMutual Private Wealth & Trust FSB increased its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 2.4% during the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 157,068 shares of the company's stock after purchasing an additional 3,751 shares during the quarter. MassMutual Private Wealth & Trust FSB's holdings in Merck & Co., Inc. were worth $12,434,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in the company. Vanguard Group Inc. lifted its stake in Merck & Co., Inc. by 0.6% during the first quarter. Vanguard Group Inc. now owns 252,513,381 shares of the company's stock worth $22,665,601,000 after purchasing an additional 1,417,274 shares during the last quarter. Wellington Management Group LLP lifted its stake in Merck & Co., Inc. by 1.1% in the first quarter. Wellington Management Group LLP now owns 81,669,651 shares of the company's stock valued at $7,330,668,000 after buying an additional 927,621 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Merck & Co., Inc. by 144.6% in the first quarter. Charles Schwab Investment Management Inc. now owns 49,229,283 shares of the company's stock valued at $4,418,820,000 after buying an additional 29,104,112 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its stake in Merck & Co., Inc. by 21.4% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 21,547,758 shares of the company's stock valued at $2,143,571,000 after buying an additional 3,791,737 shares during the last quarter. Finally, Amundi lifted its stake in Merck & Co., Inc. by 37.1% in the first quarter. Amundi now owns 13,077,716 shares of the company's stock valued at $1,130,397,000 after buying an additional 3,542,036 shares during the last quarter. 76.07% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities research analysts have issued reports on the company. Wells Fargo & Company cut their target price on Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 30th. Cantor Fitzgerald cut Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. Finally, Morgan Stanley cut their target price on Merck & Co., Inc. from $99.00 to $98.00 and set an "equal weight" rating on the stock in a research note on Thursday, July 10th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average target price of $107.44.

Merck & Co., Inc. Price Performance

NYSE:MRK opened at $81.07 on Tuesday. The business's 50-day moving average price is $82.93 and its 200 day moving average price is $82.68. The firm has a market cap of $202.50 billion, a P/E ratio of 12.49, a PEG ratio of 0.85 and a beta of 0.37. Merck & Co., Inc. has a 52-week low of $73.31 and a 52-week high of $119.38. The company has a quick ratio of 1.17, a current ratio of 1.42 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, topping analysts' consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion for the quarter, compared to analysts' expectations of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, sell-side analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be paid a $0.81 dividend. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 4.0%. Merck & Co., Inc.'s dividend payout ratio (DPR) is currently 49.92%.

About Merck & Co., Inc.

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.